Sign inJoin waitlistJoin the waitlist

Jianjun Zhang

Program Director · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas Health Science Center at Houston
2014–2015
University of Texas Health Science Center at Houston
2011–2014
Internal Medicine
Long Island Jewish Medical Center - Northwell Health
2008–2009
Memorial Sloan Kettering Cancer Center
2002–2008
Doctor of Medicine
1993–1997

Research

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy · 2016 · 4,439 citations
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Science · 2018 · 3,866 citations
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Cancer Discovery · 2018 · 1,415 citations

John Heymach
172 papers
Don Gibbons
110 papers
Xiuning Le
66 papers
Stephen Swisher
58 papers
Ara Vaporciyan
57 papers
JL
Joanna Lee
57 papers · 6 as a resident
Lingzhi Hong
49 papers · 26 as a fellow
Tina Cascone
49 papers · 3 as a fellow
BS
Boris Sepesi
48 papers
Natalie Vokes
48 papers · 1 as a fellow
Marcelo Negrao
40 papers
Lauren Byers
39 papers

Grants

Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer
National Cancer Institute · U01
PI · $3.3M · Indiana University Indianapolis
2021–2027
Molecular and Immunological Heterogeneity of Small Cell Lung Cancer (SCLC) and Its Impact on Relapse and Therapeutic Response
National Cancer Institute · U01
PI · $3M · University of Tx Md Anderson Can Ctr
2021–2026
The Molecular and Immune Evolution in the Progression of Lung Neoplasia to Invasive Adenocarcinoma
National Cancer Institute · R01
Contact PI · $1.8M · University of Tx Md Anderson Can Ctr
2019–2025
Identifying Insulin Resistance Biomarkers and Metabolomic Signature as Predictors of Precursors to Pancreatic Cancer
National Cancer Institute · R21
Contact PI · $375.2K · Indiana University Indianapolis
2016–2020

Clinical trials

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2025
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2021–2027
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2018–2026